2nd treatment for EGFR+ NSCLC with exon 20 insertion mutations
RYBREVANT® is the only treatment of its kind designed to target advanced NSCLC with exon 20 insertion mutations after platinum-based chemotherapy.
RYBREVANT® is a targeted antibody* that works against EGFR mutations in 2 ways:
Works with your body's immune system to help destroy the cancer
RYBREVANT® is different than chemotherapy, immunotherapy, and TKls (tyrosine kinase inhibitors)
*Antibodies are protective proteins that help detect harmful substances and diseases such as cancers. They are made naturally by your immune system and can also be man-made. Man-made antibodies used to treat cancer have a specific target on a cancer cell that they aim to find, attach to, and attack.
Doctor Discussion Guide
Tips and example questions for having a helpful discussion with your doctor.
Savings & Support
Once prescribed a RYBREVANT®-based treatment, connect with a Care Navigator for your support needs.
EGFR = epidermal growth factor receptor, NSCLC = non–small cell lung cancer.